Success Stories: In a Short Period of 3 Months, NIW Approval Confirmed for a Taiwanese Postdoctoral Associate in Neuroscience, Thanks to our Teamwork

Client’s Testimonial:

“Thanks a lot for the help with the case filing.”

On January 19^th, 2023, we received another EB-2 NIW (National Interest Waiver) approval for a Postdoctoral Associate in the Field of Neuroscience (Approval Notice).

General Field: Neuroscience

Position at the Time of Case Filing: Postdoctoral Associate

Country of Origin: Taiwan

State of Residence at the Time of Filing: Connecticut

Approval Notice Date: January 19^th, 2023

Processing Time: 3 months

Case Summary:

As an expert in the field of neuroscience, our NIW (National Interest Waiver) client’s proposed endeavor is to continue her research on developing novel therapies for neurodegenerative diseases and improving therapeutic outcomes by employing advanced electrophysiological and genetic manipulation techniques in order to uncover neurodegenerative mechanisms. In order to prove her worth to the national and international scientific community, our team made a database of her academic and professional accomplishments, some of which are as follows:

Her research advancing her proposed endeavor is of great importance because it advances knowledge of the mechanisms of neurodegenerative diseases.
Neurodegenerative diseases are one class of neurological disorders that impact up to a billion people each year, and from which an estimated 6.8 million die annually, and our client has researched the genetic mechanisms leading to several of those neurodegenerative diseases, including Huntington’s disease.
Her proposed endeavor also has broad implications for the United States in that it advances diagnostics and therapeutics for neurodegenerative diseases, including Alzheimer’s disease and Parkinson’s disease, which afflict millions of Americans annually.
Due to its clear national importance, her research has in fact been supported with funding from the National Institutes of Health (NIH).
Her research has resulted in 9 peer-reviewed journal articles (3 of them first-authored) and they have been cited a total of 108 times according to Google Scholar, thereby demonstrating that these publications are widely recognized and relied upon in the field of neuroscience.
She has also pursued research directly related to her proposed endeavor of employing advanced electrophysiological and genetic manipulation techniques to uncover neurodegenerative mechanisms, utilizing her extensive experience with electrophysiology, calcium imaging, behavioral tests, and genetic engineering for 7 years.
Finally, she had been able to collect 4 letters of recommendation from other experts in the field of which one said:

“Our understanding of proper neuropeptide release has been greatly enhanced by [the client’s] research into genes and their regulatory functions, and this is contributing to the creation of more accurately targeted therapeutic treatments for neurodegenerative disorders…common neurological disease including Alzheimer’s and other dementias cost the United States nearly $800 billion each year in healthcare costs and lost productivity. Considering the contributions [the client] has already made towards the mitigation of these illnesses, it is my position that the continuation of her research in the United States is of significant benefit to both the physical and economic health of those in the nation.”

These arguments helped us win the case in a short period of 3 months. We are proud of having helped her in this process and we wish her all the best in her future endeavors.

North America Immigration Law Group (Chen Immigration Law Associates) is a U.S. immigration law firm dedicated to representing corporations, research institutions, and individuals from all 50 U.S. states regarding I-140 immigration petitions. We specialize in employment-based immigration petition and have a proven record of high success rate for the categories of: EB2-NIW (National Interest Waiver), EB1-A (Alien of Extraordinary Ability), EB1-B (Outstanding Researcher/Professor) and O-1 (Alien of Extraordinary Ability).

Our Ten Thousand I-140 Approvals Provide Unprecedented Insight into the USCIS Adjudication Trend

With more than 47,000 EB-1A, EB-1B, EB-2 NIW and O-1 cases approved, we have first hand information on the manner in which the USCIS adjudicate I-140 cases. As the USCIS has constantly changed its adjudication standards for the EB-1A, EB-1B and EB-2 NIW categories, our firm's huge database of successful cases gives you unprecedented insight to USCIS adjudication trends. We carefully analyze the data for all of our cases and apply the results of our analyses toward giving our clients up-to-date advice and adapting our strategies such that we remain on par with the ever-shifting landscape of immigration law in the U.S. With us, you will always have access to important updates, strategies, and information so that you can make the most informed decisions about your case.

We Have Helped Hundreds and Thousands of Clients with Credentials and Backgrounds Similar to Yours

With our exceedingly large number of successful petitions, no matter what credentials you have, no matter your background and field of expertise, no matter your visa status or nationality, chances are we have helped hundreds or even thousands of clients just like you. Our clients are usually impressed with how well we understand their research and work. Our insight and understanding stems from the fact that we have handled many cases with elements similar to yours already, and this helps us devise the best strategies for each individual petition.

Vast Majority of Clients Came to Us Because of Referrals

For years, our firm has attracted new clients based solely on word of mouth, recommendations, and the positive collaboration experiences shared with them by their friends and family. We take pride in our reputation and work hard to ensure that we provide a green card application experience that our clients are happy to share with their friends and colleagues. That is how our approved cases grew from 600 in 2013 to over 47,000 in 2023.